Aerie Pharmaceuticals Profile

58.35
USD 1.90  3.37%
93%

Aerie Pharmaceuticals Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Aerie Pharmaceuticals Key Fundamentals

Aerie Pharmaceuticals Against Markets

Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina. Aerie Pharmaceuticals operates under Drug Manufacturers - Major classification in USA and traded on BATS Exchange. It employs 160 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Aerie Pharmaceuticals SEC Filings
Aerie Pharmaceuticals SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameAerie Pharmaceuticals
Chairman and CEOVicente AnidoView All
Analyst Consensus
Macroaxis Advice
Specialization
Healthcare, Drug Manufacturers - Major
InstrumentUSA Stock View All
RegionNorth America
LocationNORTH CAROLINA U.S.A
Business Address4301 Emperor Boulevard
ExchangeBATS Exchange
CIK Number0001337553
CUSIP00771V108
SectorHealthcare
IndustryDrug Manufacturers - Major
BenchmarkDOW
Websitewww.aeriepharma.com
Phone919 237 5300
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2019
Most Recent QuarterJune 30, 2018
Last Fiscal Year EndDecember 31, 2017
Date Short InterestAugust 31, 2018

Aerie Pharmaceuticals Directors

Aerie Pharmaceuticals Corporate Directors

David Gryska Independent Director
Julie McHugh Independent Director
Benjamin McGraw Independent Director
Check also Trending Equities. Please also try Fundamentals Matrix module to view fundamentals matrix and analyze how accounts are interrelated and interconnected with each other.
Search macroaxis.com